| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SAVA Stock Overview
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
Cassava Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.21 |
| 52 Week High | US$126.51 |
| 52 Week Low | US$13.84 |
| Beta | 0.69 |
| 1 Month Change | -16.76% |
| 3 Month Change | 17.36% |
| 1 Year Change | -81.39% |
| 3 Year Change | 1,543.09% |
| 5 Year Change | 514.27% |
| Change since IPO | -86.80% |
Recent News & Updates
Cassava Sciences GAAP EPS of -$0.48 misses by $0.06
Cassava Sciences press release (NASDAQ:SAVA): Q2 GAAP EPS of -$0.48 misses by $0.06. Cash Position - $197.2 Million of Cash and Cash Equivalents at June 30, 2022. Cognition Maintenance Study - Completion of Patient Enrollment is Expected Q4 2022. Phase 3 Program - Over 400 Patients Are Now Enrolled in Our Phase 3 Clinical Studies.
We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug
The shares of clinical-stage biotech Cassava Sciences (NASDAQ:SAVA) crashed ~44% in the pre-market after Reuters reported on Wednesday that the U.S. Justice Department had opened a criminal investigation linked to its experimental Alzheimer’s therapy simufilam. The investigation deals with whether the Texas-based biotech manipulated research results for simufilam, the news agency said, citing two people familiar with the inquiry. The Justice Department officials handling the probe are specialized in investigating whether companies or individuals have misled or defrauded multiple parties, including investors, or government agencies, The probe, similar to any other investigation conducted by the Justice Department, could lead to criminal charges or close without any charges being brought against the company. Kate Watson Moss, a lawyer for Cassava (SAVA), refused to comment on the ongoing probe. "To be clear: Cassava Sciences vehemently denies any and all allegations of wrongdoing," Watson Moss noted, adding that the firm "has never been charged with a crime, and for good reason - Cassava Sciences has never engaged in criminal conduct."
Cassava Sciences And Alzheimer's Disease: A Precipitious Path
One probably should not invest in Cassava Sciences until all investigations are completed. Alternative mechanisms of action exist that better explain Cassava Sciences' trial results than the one offered by the company. Short-term catalysts may have some effect on Cassava Sciences' stock value but the key to the company's success (or failure) are results from two phase three clinical trials. Better treatments for Alzheimer's Disease likely exist.
Shareholder Returns
| SAVA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 4.3% | -1.8% | 1.1% |
| 1Y | -81.4% | 2.0% | -13.0% |
Return vs Industry: SAVA underperformed the US Pharmaceuticals industry which returned 2% over the past year.
Return vs Market: SAVA underperformed the US Market which returned -13% over the past year.
Price Volatility
| SAVA volatility | |
|---|---|
| SAVA Average Weekly Movement | 15.1% |
| Pharmaceuticals Industry Average Movement | 11.8% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: SAVA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: SAVA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 24 | Remi Barbier | https://www.cassavasciences.com |
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019.
Cassava Sciences, Inc. Fundamentals Summary
| SAVA fundamental statistics | |
|---|---|
| Market Cap | US$810.38m |
| Earnings (TTM) | -US$60.59m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-13.4x
P/E RatioIs SAVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SAVA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$50.24m |
| Gross Profit | -US$50.24m |
| Other Expenses | US$10.35m |
| Earnings | -US$60.59m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.51 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SAVA perform over the long term?
See historical performance and comparison